2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.
To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
MacCarrone M et al. | Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor. | 2001 | Eur. J. Biochem. | pmid:11168423 |
Bisogno T et al. | The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. | 2001 | Eur. J. Biochem. | pmid:11277920 |
Di Marzo V et al. | Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. | 1999 | Eur. J. Biochem. | pmid:10447696 |
Matias I et al. | Presence and regulation of the endocannabinoid system in human dendritic cells. | 2002 | Eur. J. Biochem. | pmid:12153574 |
Di Marzo V et al. | Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. | 2009 | Eur. J. Endocrinol. | pmid:19745037 |
Sido JM et al. | Production of endocannabinoids by activated TÂ cells and BÂ cells modulates inflammation associated with delayed-type hypersensitivity. | 2016 | Eur. J. Immunol. | pmid:27064137 |
Ryan D et al. | Interactions of cannabidiol with endocannabinoid signalling in hippocampal tissue. | 2007 | Eur. J. Neurosci. | pmid:17419758 |
Béquet F et al. | CB1 receptor-mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamus. | 2007 | Eur. J. Neurosci. | pmid:18052990 |
Hájos N et al. | Endocannabinoid transport tightly controls 2-arachidonoyl glycerol actions in the hippocampus: effects of low temperature and the transport inhibitor AM404. | 2004 | Eur. J. Neurosci. | pmid:15182306 |
Kortleven C et al. | The endocannabinoid 2-arachidonoylglycerol inhibits long-term potentiation of glutamatergic synapses onto ventral tegmental area dopamine neurons in mice. | 2011 | Eur. J. Neurosci. | pmid:21410793 |
Nyilas R et al. | Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia. | 2009 | Eur. J. Neurosci. | pmid:19453631 |
Rea K et al. | Microinjection of 2-arachidonoyl glycerol into the rat ventral hippocampus differentially modulates contextually induced fear, depending on a persistent pain state. | 2014 | Eur. J. Neurosci. | pmid:24494683 |
Petrenko AB et al. | Genetic inactivation and prolonged pharmacologic inhibition of monoacylglycerol lipase have opposite effects on anesthetic sensitivity to propofol. | 2015 | Eur. J. Pharmacol. | pmid:26318148 |
Fride E et al. | Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor. | 2003 | Eur. J. Pharmacol. | pmid:12568912 |
Shimizu T and Yokotani K | Bidirectional roles of the brain 2-arachidonoyl-sn-glycerol in the centrally administered vasopressin-induced adrenomedullary outflow in rats. | 2008 | Eur. J. Pharmacol. | pmid:18234185 |
Mechoulam R et al. | Endocannabinoids. | 1998 | Eur. J. Pharmacol. | pmid:9831287 |
Shimizu T et al. | Endogenously generated 2-arachidonoylglycerol plays an inhibitory role in bombesin-induced activation of central adrenomedullary outflow in rats. | 2011 | Eur. J. Pharmacol. | pmid:21371452 |
Stella N and Piomelli D | Receptor-dependent formation of endogenous cannabinoids in cortical neurons. | 2001 | Eur. J. Pharmacol. | pmid:11513837 |
Hill MN et al. | Chronic corticosterone treatment increases the endocannabinoid 2-arachidonylglycerol in the rat amygdala. | 2005 | Eur. J. Pharmacol. | pmid:16324692 |
Oka S et al. | Suppression by WIN55212-2, a cannabinoid receptor agonist, of inflammatory reactions in mouse ear: Interference with the actions of an endogenous ligand, 2-arachidonoylglycerol. | 2006 | Eur. J. Pharmacol. | pmid:16647054 |